A Phase 1, First-in-human, Randomized, Double Blind, Placebo Controlled, Safety, Tolerability and Pharmacokinetic Study of ABY 039 in Healthy Subjects
Phase of Trial: Phase I
Latest Information Update: 27 Apr 2018
At a glance
- Drugs ABY-039 (Primary) ; ABY-039 (Primary)
- Indications Autoimmune disorders
- Focus Adverse reactions; First in man
- Sponsors Affibody
- 21 Mar 2018 Status changed from planning to recruiting, according to an Affibody media release.
- 28 Feb 2018 New trial record
- 23 Feb 2018 According to an Affibody media release, in January the UK regulatory agency MHRA approved the clinical trial application (CTA) for Phase I study with ABY-039.